Stock Data
$0.01 (0.31%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Myriad Genetics Inc is a pioneer in genetic testing and precision medicine, offering a wide range of molecular diagnostic tests. These tests are crucial in the fields of oncology, women's health, and pharmacogenomics, helping to assess risks for hereditary cancers and guide therapy decisions for various cancers including breast, ovarian, and prostate. Additionally, Myriad Genetics provides tests for prenatal screening and mental health medication guidance, collaborating with notable institutions like Illumina and Memorial Sloan Kettering Cancer Center. Founded in 1992, the company is based in Salt Lake City, Utah.
Myriad Genetics crashed to a $0.25 loss per share on mounting payer friction and a $11 million prior-period revenue adjustment, missing estimates by 332%, and now suspended full-year EBITDA guidance as it launches a "reset" efficiency program called Ascend to stabilize cash burn.
85 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
